Published in Cancer Weekly, May 10th, 2005
These are the first targets to be selected for advancement in the strategic collaboration established last year between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
"We're pleased that Abbott has elected to move forward with these targets," said Kathy Ordonez, president of Celera Genomics. "This represents an important milestone toward our goal of working with partners to develop a pipeline...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.